Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

s of the study and it was not a major reason for discontinuation during the trial.

About liraglutide

Once-daily liraglutide is the first human Glucagon-Like Peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the US as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 15, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) program includes five randomized, controlled, double-blind phase 3a studies, involving about 4,000 people with type 2 diabetes in 40 countries.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit '/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 2007 /PRNewswire-FirstCall/ --,SuperGen Inc. announced today that it ... Cancer Research,Annual Meeting on April 14-18 in Los ... of SuperGen's current oncology,programs including its lead tyrosine ... Rad51, a key protein target involved,in cancer cell ...
... -- CytImmune, a,clinical stage nanomedicine company focused ... has,been selected to present a poster abstract at ... in Chicago Illinois,June 1-5. The poster session will ... June 3. Dr. Lawrence Tamarkin, CEO of CytImmune ...
Cached Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Malaria Day at the Zoo to celebrate children helping children, a thank you ... congregations throughout West Ohio have contributed to the United Methodist initiative to end ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
(Date:8/28/2015)... ... ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse treatment ... benefit concert in Mendon, IL. Held in the Show Barn at the Adams County ... programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. Now ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices, recently released Visio Stencils for the ... HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... Stephen Robertson has announced that patients coming to Queensland ... in order to start awareness to quit smoking. This ... relieve from their smoking habit which is one of ... dubious distinction of affecting all the systems from head ...
... many for its taste grapefruit is a thing to cheer for ... found that people with gum disease who ate two grapefruits a ... ,The study was performed by Friedrich Schiller University in ... ,The explanation given is that it is due to an ...
... that the numbers of uninsured people in US have increased. ... not provide health insurance for people who are not disabled ... are recent college graduates and patients from middle-class and suburban ... group of 20 to 64 are devoid of insurance. The ...
... Muslims were monitored for the presence of bird flu infection ... found to be devoid of any infection will continue their ... by the second week of January. ,There has ... viral mutation that would enable the human-human transmission. The probability ...
... The Government promised in June last year that every patient ... computerized 'choose and book' system by the end // of ... - the latest month for which figures are available - ... ,The Department of Health figures show that between October ...
... those small portions help us keep over indulgence at bay.Contrary to ... // into short , wide glasses than into tall, narrow ones ... hold more. The study finds mention in BMJ. ... professional bartenders do the same mistake or so to call it. ...
Cached Medicine News:Health News:GP's online referral scheme in UK 'a national IT disaster' 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: